Over halfway through Phase 2 trials. The new restructured board and management are delivering as they said they would.
Considering this is a software plug in to sleep centres with almost zero COGS, the economics of this type of medical technology play is alomst unrivalled.
If FDA approval is given, the company has a clearly defined moat, with a large TAM see exert from above ann(FDA clearance would unlock a significant market opportunity for the Company. It is estimated that 60 million people in the US suffer from poor sleep quality1 and that 75% of people diagnosed with depression suffer from disrupted sleep patterns) and a product with an amazing GP margin.
Seems pretty good value at a MC of only $13m
Over halfway through Phase 2 trials. The new restructured board...
Add TRI (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.9¢ |
Change
0.003(11.5%) |
Mkt cap ! $11.88M | |||
| Open | High | Low | Value | Volume |
| 2.5¢ | 2.9¢ | 2.5¢ | $35.01K | 1.349M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 543508 | 2.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.9¢ | 109583 | 1 |
View Market Depth
| Last trade - 15.32pm 06/06/2024 (20 minute delay) ? |
|
|||||
|
Last
2.6¢ |
Change
0.003 ( 0.00 %) |
||||
| Open | High | Low | Volume | ||
| 2.6¢ | 2.6¢ | 2.6¢ | 142477 | ||
| Last updated 14.54pm 06/06/2024 ? | |||||
| TRI (ASX) Chart |